Royalty Pharma plc


Want a discount? Become a member by purchasing Annual Subscription!
SKU: RPRX Category:


Royalty Pharma: Will The Growing Synthetic Royalty Transactions Continue Their Trend In 2024?


Royalty Pharma reported a strong year of results in 2023, which demonstrated significant enhancements of its portfolio. The company reported 9% growth in portfolio receipts and an increase in royalty receipts by 8%. A total of $2.2 billion was deployed in cash for transactions while $4 billion in transactions was announced, making it a remarkable year for capital allocation. Royalty Pharma also implemented a $1 billion buyback program, reacting to the perceived disconnect between the company’s share price and its strong fundamental outlook. This came in tandem with its 2024 guidance, which estimates portfolio receipts to range between $2.6 billion and $2.7 billion based on expected underlying portfolio growth of 5% to 9%.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $99 annual subscription!